Clinical Trial Update: Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update on frontline venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia, reporting activity and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED